Free Publications

Search for cll returned 195 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

Update on CLL and Small Cell Lymphoma

Please join The Leukemia & Lymphoma Society (LLS) for an education program intended for patients, caregivers, concerned others and healthcare professionals. Update on Chronic Lymphocytic Leukemia and Small Cell Lymphoma Tuesday, January 24th, 2017
5:30pm - 7:30pm UGA Center for Continuing Education
1197 South Lumpkin Street
Athens, GA 30602
(Parking is available for a fee in South Campus parking deck adjacent to the Center or on surface streets for a ...

Read more

Living with Chronic Lymphocytic Leukemia (CLL)

July 12, 2017

Topics Covered We invite you to learn more about: How CLL is diagnosed Treatment planning for CLL The impact of new and emerging therapies Managing side effects How to communicate effectively with your treatment team   Speaker Danielle M. Brander, MD
Lead, Duke CLL & Indolent Lymphoma Clinic
Division Hematologic Malignancies & Cellular Therapy
Department of Medicine, Duke University
Duke Cancer In ...

  • Photo
  • PDF
  • AUDIO
Read more

Living well with CLL

Join us for an exciting new program taking you through all phases of the CLL journey: from diagnosis through treatment and beyond into survivorship.

Location
LockKeepers
8001 Rockside Road
Valley View, OH 44125

Speakers
Brian T. Hill, MD, PhD, Cleveland Clinic
Linda Baer MSN, APRN, AOCNP, University Hospitals Seidman Cancer Center

Program Description
This program is designed to provide attendees with essential in ...

Read more

Living well with CLL: diagnosis, treatments and support.

Join us for an exciting new program taking you through all phases of the CLL journey: from diagnosis through treatment and beyond into survivorship.

Location
Marriott Minneapolis Airport
2020 American Blvd. East
Bloomington, MN 55425

Speakers
Veronika Bachanova, MD, PhD
William Robiner, PhD, ABPP, LP
                 
Program Description
This program is designed to pr ...

Read more

Advances in Blood Cancers: Making NHL & CLL Treatment Decisions

The Leukemia & Lymphoma Society's Information Specialists are master's level social workers, nurses and health educators who can help you navigate through treatment, financial and social challenges and give accurate, up-to-date disease and treatment information. Speak with an Information Specialist:  Call (800) 955-4572 Email Live Chat We invite you to watch the new video, Advances in Blood Cancers: Making NHL & CLL Treatment Decisions to le ...

  • Photo
Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.